NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

I previously mentioned that I had thoughts about the use of Bevacizumab in this trial.

At the time of JTM, it was reported that 108 out of 331 patients (31%), had received Bev "while on study"
So these are not censored patients.

Since that time there would have been quite a few more patients who subsequently received Bev, perhaps moving the percentage up towards 40%.
Now it is easy to say 'Bev doesn't extend survival' and I would agree with that. So it may not confound the OS data in the traditional sense.
But I believe that Bev may 'cap' survival duration in many individuals.
And my hypothesis is that the TOP 100 survivors will contain a disproportionate amount of patients who did not receive Bev.
And that OS36 and OS48 percentages may be higher for the entire cohort if nobody received Bev.

Entirely unprovable unless comparitive figures were released, and may be of only academic interest.
I won't expand further, otherwise I'll have to start calling it Avistan or something...


Just sayin'.